Advancements in Treating Early-Stage Biochemical Recurrence in Hormone-Sensitive Prostate Cancer: Baseline Assessment
Primary Audience:
This activity is intended to meet the educational needs of urologists, medical oncologists and radiation oncologists involved in the care of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).
The following questions are designed to assess your knowledge and practice of patients with nmHSPC.
Catherine Handy Marshall, MD, MPH
Assistant Professor of Oncology
Internal Medicine, Oncology
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Catherine Marshall is an Assistant Professor in the Department of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include internal medicine and oncology.
She received her M.D. and M.P.H. from Johns Hopkins, where she also completed her residency and an oncology fellowship.
1.
Develop the ability to appropriately risk-stratify patients with biochemical recurrence after primary therapy for nmHSPC based on existing data and guidelines.
2.
Understand the various treatment options and their indications, benefits, and risks for patients with nmHSPC.
3.
Develop a deeper understanding of the impact of initial treatment choice on subsequent treatment options for patients with high-risk nmHSPC.
4.
Develop the ability to effectively utilize shared clinical decision-making tools to facilitate collaborative and patient-centered decision-making for early-stage prostate cancer treatment.
